-
April 26, 2013
Stephen Whitehead tells the annual ABPI conference that the health service is going through dramatic change and the industry is struggling to keep up
Full story
-
February 12, 2013
Cost regulators for the National Health Service in Scotland have agreed to fund the use of Pfizer and Bristol Myers Squibb's blood thinner Eliquis to prevent stroke and embolism.
Full story
-
January 23, 2013
Third of the new oral anticoagulants to be appraised by NICE
Full story
-
June 07, 2012
In final draft guidance, NICE says it recommends the use of Bayer Healthcare's Xarelto as an option for treating DVT and preventing recurrent DVT and PE in adults diagnosed with acute DVT.
Full story
-
May 24, 2012
In final guidance, NICE has recommended the use of Bayer HealthCare's Xarelto (rivaroxaban) as an option for the prevention of stroke and systemic embolism in people with atrial fibrillation (AF).
Full story
-
May 04, 2012
Eagerly-anticipated results from one of the largest-ever studies of heart failure suggest that treatment with cheap aspirin therapy is as effective as warfarin
Full story
-
April 03, 2012
Following the receipt of further evidence from Bayer HealthCare of Xarelto's clinical and cost-effectiveness, NICE has issued final draft guidance recommending it an option for the prevention of stroke and systemic embolism in people with atrial fibrillation.
Full story
-
March 29, 2012
Boehringer Ingelheim has announced that it is reducing the cost of its oral anticoagulant Pradaxa (dabigatran etexilate) by 13%, to £2.20 per day, from April 1.
Full story
-
March 15, 2012
Final guidance from NICE recommends Boehringer Ingelheim's Pradaxa (dabigatran) for the prevention of stroke and systemic embolism in people with atrial fibrillation (AF).
Full story
-
March 13, 2012
NICE has asked Bayer for more evidence concerning the clinical and cost effectiveness of Xarelto (rivaroxaban) in the treatment of deep vein thrombosis (DVT).
Full story